Previous 10 | Next 10 |
Phase 3 URIROX-1 Trial Achieves Primary Endpoint with Statistically Significant Reduction in Urinary Oxalate in Patients with Enteric Hyperoxaluria Phase 2 Study 206 Trial Demonstrates Substantial Plasma Oxalate Reduction in Patients with Enteric Hyperoxaluria and Advanced Chronic Kid...
If you don't know history, then you don't know anything. You are a leaf that doesn't know it is part of a tree . " - Michael Crichton Today, we look at a small 'Busted IPO' focusing on metabolic disorders. Company Overview: Allena Pharmaceuticals ( ALNA ) is a Newton, Massachusetts ba...
NEWTON, Mass., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, t...
Allena Pharmaceuticals ( ALNA -2.7% ) completes enrollment in a Phase 3 clinical trial, URIROX-1 , evaluating reloxaliase in patients with enteric hyperoxaluria, elevated levels of oxalate in the urine due to malabsorption of fat, a common consequence of intestinal resection or bypass s...
NEWTON, Mass., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, ...
NEWTON, Mass., Sept. 11, 2019 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, ...
Allena Pharmaceuticals ( ALNA ) is focused on rare metabolic and kidney disorders. Its lead drug, Reloxiliase, degrades oxalate in the gastrointestinal tract, and is being studied to treat enteric hyperoxaluria ( EH ). EH is a form of secondary hyperoxaluria that can cause nephrolithiasis (kid...
NEWTON, Mass., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, t...
Allena Pharmaceuticals (NASDAQ: ALNA ): Q2 GAAP EPS of -$0.54 in-line. More news on: Allena Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
-- Interim Data from Study 206 Demonstrated Substantial Treatment Effect in Patients with Enteric Hyperoxaluria and Advanced Chronic Kidney Disease, Including Robust Reductions in Both Urine and Plasma Oxalate -- -- Closed $10.0 Million Registered Direct Offering, Extending Cash Runwa...
News, Short Squeeze, Breakout and More Instantly...
Allena Pharmaceuticals Inc. Company Name:
ALNA Stock Symbol:
NASDAQ Market:
Allena Pharmaceuticals Inc. Website:
Buying Penny Stocks on July 29th? Here’s What You Need to Know If you’re looking for the best penny stocks to buy right now, there are hundreds of options to choose from. As a result, it all comes down to finding the best penny stocks that fit your trading strateg...
NEWTON, Mass., July 19, 2022 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) (“Allena” or the “Company”), a biopharmaceutical company deploying its novel oral biologic platform to discover, develop and commercialize first-in-class, oral enzyme the...
NEWTON, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorde...